Brief: Guerbet: National Medical Products Administration Approves Lipiodol Ultra-Fluid in China
June 9 (Reuters) - GUERBET SA GRBT.PA :
* NATIONAL MEDICAL PRODUCTS ADMINISTRATION APPROVES
LIPIODOL®
ULTRA-FLUID FOR TRANS-ARTERIAL CHEMOEMBOLIZATION OF INTERMEDIATE
STAGE HEPATOCELLULAR CARCINOMA (HCC) IN ADULT PATIENTS IN CHINA
Source text: https://bit.ly/2Uq1CpM
Further company coverage: GRBT.PA
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Guerbet SA
See all newsBrief: Guerbet Revenue At 30 September 2026 Of EUR 573.8 Million
Corrected: French medical imaging firm Guerbet's 9M revenue slips on China sales drop
French medical imaging firm Guerbet H1 EBITDA margin falls on Raleigh site costs
Brief: Guerbet H1 EBITDA €30.6 Mln
French and Benelux stocks-Factors to watch